|

Golcadomide Clinical Trials

4 actively recruiting trials across 3 locations

▼ -1 trial since August 2026

Also known as: BMS 986369, BMS-986369, BMS986369, CC -99282, CC 99282 +6 more

Pipeline

Phase 2: 1Phase 3: 1Phase 1/2: 2

Top Sponsors

  • The Lymphoma Academic Research Organisation1
  • Mayo Clinic1
  • Celgene1
  • Bristol-Myers Squibb1

Indications

  • Cancer4
  • Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma1
  • Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type1
  • Refractory Intravascular Large B-Cell Lymphoma1
  • Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified1

Other1 trial

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
Phase 1/2

Birmingham, Alabama1 trial

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Local Institution - 0225

Phase 3

Phoenix, Arizona1 trial

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Mayo Clinic in Arizona - Phoenix

Phase 1/2

Scottsdale, Arizona1 trial

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Mayo Clinic in Arizona

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.